WaveMan
WaveMan · Company
IMTX · Immatics N.V.
> Search tickers & screens ⌘K
LIVE
← All companies

IMTX Immatics (IMTX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001809196
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
37
13F, latest reported quarter

What the filings say about IMTX

Insiders, 180 days
+$7.5M net bought
1 buyer

Immatics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Immatics N.V. insiders bought a net $7.5M of stock across 1 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.

Insider
Filed
Shares
Value
Since filing
BUY
2026-08-27 SECtraded 2026-08-26
863,060
$7.5M
-22.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 7.7% of the 11,246,516 shares held after it.
  • No other insider bought within 30 days.
  • 37 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director PERCEPTIVE ADVISORS LLC bought about $7.5M of IMTX on Aug 26, 2026, the largest insider purchase at the company on our record; 37 funds added in the latest 13F quarter.
1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$7.5M over 180 days
+$7.5M over 90 days
more than 95% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
37 funds bought in last quarter
below 59% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
5.3% of the float short (float per yahoo 2026-10-26) · 4.2 days to cover · settled 2026-09-30
below 61% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch IMTX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-27.8%12M
-34%-17%+0%+17%2025-102025-122026-022026-042026-062026-082026-10 2026-08-26 · PERCEPTIVE ADVISORS LLC bought $7.5M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns IMTX: institutional holders (13F)

13F holdings, latest reported quarter
12,946,176 sh
$131.1M
$113.4M
$105.2M
$96.3M

Congress trades in IMTX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IMTX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

IMTX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALPS Medical Breakthroughs ETF
$1.6M position · as of 2026-05-31
1.0%
T. Rowe Price Health Care ETF
$199.8K position · as of 2026-06-30
0.9%
T. Rowe Price Institutional Small-Cap Stock Fund
$28.9M position · as of 2026-06-30
0.6%
T. Rowe Price Small-Cap Stock Fund, Inc.
$53.1M position · as of 2026-06-30
0.6%
T. Rowe Price Small-Cap Value Fund, Inc.
$52.3M position · as of 2026-06-30
0.5%
Small Company Value Trust
$652.4K position · as of 2026-06-30
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $7.5M bought by insiders over 180 days, 37 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Same sector, ranked by filing activity
Sector by SEC SIC code

IMTX financials

Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Net income-$196.4M$15.2M-$94.6M$27.7M
SEC XBRL, fiscal years, as known on 2026-10-27

IMTX Stock Sonar score 3/7 axes

Find similar shapesCompare

IMTX ranks highest on insider conviction (76th percentile) and risk and compliance (57th), and lowest on institutional and government (41st), among Pharma & Biotech peers.

Insider conviction
76
Inputs
  • Net Form 4 buying (codes P and S), 180d$7.5M · 95 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
41
Inputs
  • Funds adding, latest quarter37 · 41 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
57
Inputs
  • Short interest, % of float+5.3% · 57 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Growth, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

IMTX filings, in plain words

Are Immatics insiders buying or selling IMTX?

In the 180 days to 2026-10-27, Immatics insiders were net buyers, a net $7.5M across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-27, Immatics insiders were net buyers of IMTX, a net $7.5M across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing